Latest News
Vector Science & Therapeutics secures three-year manufacturing partnership with MPP Group to expand peptide pipeline
11 May 2026 - Medical technology company Vector Science & Therapeutics (TSXV: PAIN) announced on Monday that it has entered a three-year development and manufacturing agreement with MPP Group LLC to support the production of pharmaceutical-grade ...
Anixa Biosciences reports extended survival signals in Phase 1 ovarian cancer CAR-T trial
11 May 2026 - Biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) on Monday reported updated positive survival observations from its ongoing Phase 1 trial of liraltagene autoleucel (lira-cel), an investigational CAR-T therapy for recurrent ova...
Oncopeptides plans EMA filing to broaden Pepaxti indication
11 May 2026 - Oncopeptides AB (STO:ONCO), a Swedish biotech company focused on difficult-to-treat cancers, said on Monday that it intends to submit a Type II variation application to the European Medicines Agency (EMA) to expand the indication for Pe...
GSK partners with SBP Group to accelerate China launch of bepirovirsen
11 May 2026 - Biopharmaceutical company GSK plc (LSE/NYSE: GSK) announced on Monday that it has entered an exclusive strategic collaboration with Sino Biopharmaceutical Limited through subsidiary Chia Tai Tianqing Pharmaceutical Group Co, Ltd to supp...
Poolbeg Pharma secures Canadian patent grant for POLB 001
11 May 2026 - Biopharmaceutical company Poolbeg Pharma plc (AIM: POLB) disclosed on Monday that it has received formal notification that the Canadian patent office has granted its patent application covering POLB 001 for the prevention of cancer immu...